TrueWealth by TrueData – Live AI Summaries & Real-Time BSE/NSE Corporate Announcements
Copyright © TrueWealth 2025
Made with in INDIA
TrueData – Authorized Market Data Vendor for NSE, BSE, MCX (Official Logo)
Latest AnnouncementsToday 0
Upcoming Events
News Feed

  • No Data Found

A

Abbott India Ltd

ABBOTINDIA

abbott.co.in NSE ABBOTINDIA BSE500488 ISIN: INE358A01014
₹26200
1.33% (+343.90)
Website

abbott.co.in

NSE
NSE

ABBOTINDIA

BSE
BSE

500488

ISIN

INE358A01014

Announcement Post Market Close
Outcome :: AGM
Aug 14 2026, 06:19:58 PM

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Voting Results along with Consolidated Scrutinizer''s Report for the 82nd Annual General Meeting held on August 13, 2026.

Abbott India Ltd
Since 1910

Abbott India Ltd is a leading subsidiary of Abbott Laboratories, a global healthcare company, and has been operating in India since 1910. The company is recognized for its deep-rooted presence in pharmaceuticals, specializing in the manufacture, marketing, and distribution of a broad portfolio which includes proprietary and over-the-counter (OTC) medicines. Its therapeutic focus spans gastroenterology, women’s health, central nervous system, metabolic disorders, anti-infectives, and pain management, catering to a wide spectrum of healthcare needs in India.

Sector
Healthcare/Pharmaceuticals Sector
Recent Announcements (…Last 3 Days)
A
14 Aug 2026•18:19:58
Outcome::AGM
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

Voting Results along with Consolidated Scrutinizer''s Report for the 82nd Annual General Meeting held on August 13, 2026.

A
14 Aug 2026•18:03:26
General::Newspaper Publication
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication

A
13 Aug 2026•17:18:04
Outcome::AGM
Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings of 82nd Annual General Meeting of the Company.

A
12 Aug 2026•19:18:23
Outcome::Financial Results
Unaudited Financial Results For The Quarter Ended June 30, 2026.

Unaudited financial results for the quarter ended June 30, 2026.

A
12 Aug 2026•18:45:19
Outcome::Board Meeting Outcome
Board Meeting Outcome for Outcome Of Board Meeting

Outcome of Board Meeting

A
04 Aug 2026•16:57:43
Intimation::Board Meeting
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2026.

Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

A
04 Aug 2026•12:16:24
General::Newspaper Publication
Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities

truewealth
Request an update
Abbott India Ltd
Healthcare/Pharmaceuticals SectorSince 1910
About

Abbott India Ltd is a leading subsidiary of Abbott Laboratories, a global healthcare company, and has been operating in India since 1910. The company is recognized for its deep-rooted presence in pharmaceuticals, specializing in the manufacture, marketing, and distribution of a broad portfolio which includes proprietary and over-the-counter (OTC) medicines. Its therapeutic focus spans gastroenterology, women’s health, central nervous system, metabolic disorders, anti-infectives, and pain management, catering to a wide spectrum of healthcare needs in India.

With a head office in Mumbai, Abbott India Ltd serves both the urban and rural markets across the country. Its operations are supported by a well-established sales and distribution network, robust research and development activities, and strategic collaborations. Abbott India places strong emphasis on compliance, innovation, and high-quality standards, aligning with both its global parent’s philosophy and India’s evolving healthcare environment.

Business Model & Strategy

Abbott India Ltd generates revenue primarily from the marketing and distribution of branded generic pharmaceuticals, prescription medications, and OTC products. It follows a hybrid model that balances in-house manufacturing with outsourced production, enabling operational efficiency and flexibility. A major aspect of its strategy involves rigorous investment in product innovation and lifecycle management, launching new formulations and line extensions across high growth therapeutic segments.

The company actively pursues growth through portfolio expansion, digital outreach to healthcare professionals, strong field force engagement, and expanding access to tier-II and tier-III Indian cities. Strategic partnerships, regulatory compliance, and supply chain optimization are integral to its sustainable business practices. Abbott India also leverages the global expertise and pipeline of its parent, Abbott Laboratories, to maintain a competitive edge in the Indian pharmaceutical landscape.

Management Overview
11 Members
Mr.Munir Shaikh
Non-Executive - Non Independent Director-Chairperson
Mr.Kartik Rajendran
Executive Director-MD
Ms.Anisha Motwani
Non-Executive - Independent Director
Mr.Sudarshan Jain
Non-Executive - Independent Director
Ms.Shalini Kamath
Non-Executive - Independent Director
Mr.Ambati Venu
Non-Executive - Non Independent Director
Mr.Kaiyomarz Marfatia
Non-Executive - Non Independent Director
Ms.Alison Davies
Non-Executive - Non Independent Director
Mr.Darshan Gada
Non - Executive Non -Independent Director
Ms.Maithilee Mistry
Chief Financial Officer
Ms.Sangeeta Shetty
Company Secretary & Compliance Officer
Awards & Recognition
5 Awards
  • Great Place to Work® Certified™: Consistently listed in India’s 'Best Workplaces in Health & Wellness' (2023, 2024)
  • Ranked among India's Most Trusted Pharmaceutical Brands (ET Brand Equity, 2024)
  • Featured in 'India’s Top 50 Companies in ESG' (2024, Sustainalytics / ET Prime)
  • Recipient, India Pharma Innovation Award (2023, Pharmexcil)
  • Listed in Fortune India’s 'Top 500 Companies' (2024)
Market Information
NIFTY TOTAL MARKETNIFTY MIDCAP 150NIFTY 500NIFTY MNCNIFTY LARGEMID250NIFTY MIDSML 400NIFTY PHARMANIFTY HEALTHCARENIFTY500 MULTICAPNIFTY M150 QLTY50
ISIN INE358A01014
Sector Healthcare/Pharmaceuticals
IndustryPharmaceuticals
Company Timeline

114+ Years of Excellence | 8 Major Milestones

1910

Abbott establishes its presence in India.

1944

Incorporation of Abbott India Ltd as a legal entity.

1965

Commissioning of first manufacturing facility in Mumbai.

2003

Listed on the Bombay Stock Exchange and National Stock Exchange.

2010

Celebrated 100 years of operations in India.

2018

Launched new formulations in women's health and gastroenterology.

2022

Expanded rural outreach via digital healthcare initiatives.

2024

Recognized as a Best Workplace in Health & Wellness; ESG leadership reinforced.

Coming Soon

The Next Evolution

Contact Information
Registered Office

Unit No.3, Corporate Park, Sion - Trombay Road, Chembur

Tel: 022-50461000 / 2000 / 1119 / 1117 / 1116 / 67978888,

Fax: 022-50169400,

Email: investorrelations.india@abbott.com; webmaster@abbott.com

Website: abbott.co.in

Registrars

KFin Technologies Ltd

Tel: 040 - 67162222

Email: einward.ris@kfintech.com

Corporate Actions
19
PurposeEx DateRecord DateBC StartBC End
Special Dividend
₹131 per share
24 Jul 2026
Friday
24 Jul 2026
Friday
-
-
Final Dividend
₹525 per share
24 Jul 2026
Friday
24 Jul 2026
Friday
-
-
Final Dividend
₹475 per share
25 Jul 2025
Friday
25 Jul 2025
Friday
-
-
Final Dividend
₹410 per share
19 Jul 2024
Friday
19 Jul 2024
Friday
-
-
Final Dividend
₹180 per share
21 Jul 2023
Friday
21 Jul 2023
Friday
-
-
Special Dividend
₹145 per share
21 Jul 2023
Friday
21 Jul 2023
Friday
-
-
Final Dividend
₹145 per share
02 Aug 2022
Tuesday
-
04 Aug 2022
Thursday
10 Aug 2022
Wednesday
Special Dividend
₹130 per share
02 Aug 2022
Tuesday
-
04 Aug 2022
Thursday
10 Aug 2022
Wednesday
Final Dividend
₹120 per share
19 Jul 2021
Monday
-
21 Jul 2021
Wednesday
27 Jul 2021
Tuesday
Special Dividend
₹155 per share
19 Jul 2021
Monday
-
21 Jul 2021
Wednesday
27 Jul 2021
Tuesday
Final Dividend
₹107 per share
28 Aug 2020
Friday
-
01 Sep 2020
Tuesday
07 Sep 2020
Monday
Special Dividend
₹143 per share
28 Aug 2020
Friday
-
01 Sep 2020
Tuesday
07 Sep 2020
Monday
Final Dividend
₹50 per share
13 Aug 2019
Tuesday
-
16 Aug 2019
Friday
22 Aug 2019
Thursday
Special Dividend
₹15 per share
13 Aug 2019
Tuesday
-
16 Aug 2019
Friday
22 Aug 2019
Thursday
Final Dividend
₹50 per share
10 Jul 2018
Tuesday
-
12 Jul 2018
Thursday
18 Jul 2018
Wednesday
Special Dividend
₹5 per share
10 Jul 2018
Tuesday
-
12 Jul 2018
Thursday
18 Jul 2018
Wednesday
Final Dividend
₹40 per share
10 Jul 2017
Monday
-
12 Jul 2017
Wednesday
18 Jul 2017
Tuesday
Final Dividend
₹35 per share
08 Jul 2016
Friday
-
12 Jul 2016
Tuesday
18 Jul 2016
Monday
Final Dividend
₹31 per share
22 Jul 2015
Wednesday
-
24 Jul 2015
Friday
29 Jul 2015
Wednesday
Interim Dividend
Final Dividend
Dividend
Bonus
Split
Rights Issue
Other
.dsf..
Market Cap
₹55,535 Cr.
Curr. Price
₹26,200
52W High/Low
₹32,775 / 25,150
P/E (TTM)
34.39
Book Value
₹2246.75
Price To Book Ratio
11.63
ROE
blog-img
ROE vs ROCE - Which Matters More for Evaluating Companies?
32.51 %
ROCE
blog-img
ROE vs ROCE - Which Matters More for Evaluating Companies?
111.13 %
EPS (TTM)
blog-img
What is EPS & what is its significance?
₹759.85
Face Value
₹10.00
Dividend Yield
2.51 %
Manage Ratio
11 ratios selected

Date Basis

Time Range

EPS
truewealth
Request an update
FINANCIALS
Revenue
+1.1%
7,004.4 Cr
3Y +24%
5Y +51%
HIST AVG
Operating Income
+4.1%
1,969.0 Cr
3Y +48%
5Y +103%
HIST AVG
Net Income
+4.0%
1,614.7 Cr
3Y +49%
5Y +125%
HIST AVG
EPS
+4.0%
759.0
3Y +49%
5Y +125%
HIST AVG
Op. Cash Flow
+0.0%
1,841.2 Cr
3Y +17%
5Y +54%
HIST AVG
ABBOTINDIA - Quarterly Results

Standalone Figures in Rs. Crores

Quarterly Results+Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026TTM
Income + - - - - - - - - 867 1,004 985 936 1,028 1,084 1,106 989 1,092 1,077 1,110 1,112 1,237 1,240 1,243 1,276 1,331 1,413 1,366 1,393 1,535 1,550 1,493 1,520 1,625 1,693 1,686 1,681 1,811 1,827 1,794 1,785 1,8890
Expenses + - - - - - - - - 738 790 806 759 842 867 855 840 849 833 873 910 973 983 976 984 1,056 1,058 1,032 1,084 1,145 1,134 1,071 1,130 1,188 1,214 1,198 1,198 1,318 1,281 1,285 1,254 1,3170
Profit + - - - - - - - - 82 138 117 113 117 178 187 111 180 181 177 152 196 192 199 211 206 266 247 231 290 313 311 287 328 359 361 367 366 415 376 395 4290
Tax +--------46766363703864386263614968656781709088771001021111031091211271161271311331361440
EPS + - - - - - - - - 39 65 55 53 55 84 88 52 85 85 83 72 92 91 94 99 97 125 116 109 137 147 146 565 154 169 170 173 172 195 177 186 2020
Ratios +-
Cash Flow

Standalone Figures in Rs. Crores

Quarterly Cash FlowJun 2016

Sep 2016

Dec 2016

Mar 2017

Jun 2017

Sep 2017

Dec 2017

Mar 2018

Jun 2018

Sep 2018

Dec 2018

Mar 2019

Jun 2019

Sep 2019

Dec 2019

Mar 2020

Jun 2020

Sep 2020

Dec 2020

Mar 2021

Jun 2021

Sep 2021

Dec 2021

Mar 2022

Jun 2022

Sep 2022

Dec 2022

Mar 2023

Jun 2023

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Jun 2026

-
Cash Flow Operating-----------------252-727-467-948-370-893-684-1,213-482-1,012-522-1,319--
Cash Flow Investing-----------------348--72--15--396-401--148-372--416-763-182-548--371--
Cash Flow Financing------------------556--582--611--637--611--639--717--745--899--925--1,040--1,066--
Cash Increase Decrease-----------------43-73--159--86-160-107-338-52-346-269-31--118--
Net Cash And Cash Equivalent-----------------145-145-218-218-133-133-240-240-292-292-561-561--
Balance Sheet

Standalone Figures in Rs. Crores

Annual Balance Sheet+Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-
Assets + - - - 2,941 3,547 3,840 4,224 4,556 5,193 5,917 6,502-
Equity And Liabilities + - - - 2,941 3,547 3,840 4,224 4,556 5,193 5,917 6,502-
Shareholding Pattern

Numbers in Percentages

Quarterly SHP

Announcement Date

Jun 2016

30 Jun '16

Sep 2016

30 Sep '16

Dec 2016

31 Dec '16

Mar 2017

31 Mar '17

Jun 2017

30 Jun '17

Sep 2017

30 Sep '17

Dec 2017

31 Dec '17

Mar 2018

31 Mar '18

Jun 2018

10 Jul '18

Sep 2018

31 Oct '18

Dec 2018

15 Jan '19

Mar 2019

12 Apr '19

Jun 2019

12 Jul '19

Sep 2019

11 Oct '19

Dec 2019

10 Jan '20

Mar 2020

10 Apr '20

Jun 2020

07 Aug '20

Sep 2020

13 Oct '20

Dec 2020

11 Jan '21

Mar 2021

12 Apr '21

Jun 2021

13 Jul '21

Sep 2021

11 Oct '21

Dec 2021

13 Jan '22

Mar 2022

12 Apr '22

Jun 2022

08 Jul '22

Sep 2022

21 Oct '22

Dec 2022

13 Jan '23

Mar 2023

12 Apr '23

Jun 2023

09 Jul '23

Sep 2023

11 Oct '23

Dec 2023

15 Jan '24

Mar 2024

10 Apr '24

Jun 2024

16 Jul '24

Sep 2024

14 Oct '24

Dec 2024

16 Jan '25

Mar 2025

18 Apr '25

Jun 2025

12 Jul '25

Sep 2025

15 Oct '25

Dec 2025

14 Jan '26

Mar 2026

10 Apr '26

Jun 2026

17 Jul '26

-
Goverments ------------------------------------------
Promoter And Promoter Group - - - - - - - - 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99% 74.99%-
Non Institutions --------15.72%16.15%15.95%15.98%15.80%16.43%16.93%17.30%17.69%17.52%18.09%18.47%18.03%17.89%18.04%17.27%16.86%16.95%16.42%16.20%16.04%16.00%16.10%15.92%16.02%15.85%15.84%15.93%15.66%15.75%15.83%15.81%15.85%-
FII - - - - - - - - - - - - - - - - - - - - - - - - - 0.20% 0.20% 0.19% 0.19% 0.18% 0.18% 0.18% 0.18% 0.16% 0.16% 0.16% 0.16% 0.16% 0.18% 0.26% 0.38%-
DII - - - - - - - - - - - - - - - - - - - - - - - - - 7.86% 8.39% 8.62% 8.78% 8.83% 8.74% 8.91% 8.81% 8.99% 9.01% 8.92% 9.19% 9.11% 9.00% 8.93% 8.78%-
Total --------100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%-

Abbott India Ltd

Pharmaceuticals
Last Updated: June 18, 2025

Abbott India Ltd

Abbott India Ltd is a leading subsidiary of Abbott Laboratories, a global healthcare company, and has been operating in India since 1910. The company is recognized for its deep-rooted presence in pharmaceuticals, specializing in the manufacture, marketing, and distribution of a broad portfolio which includes proprietary and over-the-counter (OTC) medicines. Its therapeutic focus spans gastroenterology, women’s health, central nervous system, metabolic disorders, anti-infectives, and pain management, catering to a wide spectrum of healthcare needs in India.

With a head office in Mumbai, Abbott India Ltd serves both the urban and rural markets across the country. Its operations are supported by a well-established sales and distribution network, robust research and development activities, and strategic collaborations. Abbott India places strong emphasis on compliance, innovation, and high-quality standards, aligning with both its global parent’s philosophy and India’s evolving healthcare environment.

Healthcare/Pharmaceuticals SectorSince 1910
Business Model & Strategy

Abbott India Ltd generates revenue primarily from the marketing and distribution of branded generic pharmaceuticals, prescription medications, and OTC products. It follows a hybrid model that balances in-house manufacturing with outsourced production, enabling operational efficiency and flexibility. A major aspect of its strategy involves rigorous investment in product innovation and lifecycle management, launching new formulations and line extensions across high growth therapeutic segments.

The company actively pursues growth through portfolio expansion, digital outreach to healthcare professionals, strong field force engagement, and expanding access to tier-II and tier-III Indian cities. Strategic partnerships, regulatory compliance, and supply chain optimization are integral to its sustainable business practices. Abbott India also leverages the global expertise and pipeline of its parent, Abbott Laboratories, to maintain a competitive edge in the Indian pharmaceutical landscape.

Management Overview 11 Total Members
logo
Mr.Munir Shaikh
Non-Executive - Non Independent Director-Chairperson
logo
Mr.Kartik Rajendran
Executive Director-MD
logo
Ms.Anisha Motwani
Non-Executive - Independent Director
logo
Mr.Sudarshan Jain
Non-Executive - Independent Director
logo
Ms.Shalini Kamath
Non-Executive - Independent Director
logo
Mr.Ambati Venu
Non-Executive - Non Independent Director
logo
Mr.Kaiyomarz Marfatia
Non-Executive - Non Independent Director
logo
Ms.Alison Davies
Non-Executive - Non Independent Director
logo
Mr.Darshan Gada
Non - Executive Non -Independent Director
logo
Ms.Maithilee Mistry
Chief Financial Officer
logo
Ms.Sangeeta Shetty
Company Secretary & Compliance Officer
Awards & Recognition 5 Awards
Great Place to Work® Certified™: Consistently listed in India’s 'Best Workplaces in Health & Wellness' (2023, 2024)
Ranked among India's Most Trusted Pharmaceutical Brands (ET Brand Equity, 2024)
Featured in 'India’s Top 50 Companies in ESG' (2024, Sustainalytics / ET Prime)
Recipient, India Pharma Innovation Award (2023, Pharmexcil)
Listed in Fortune India’s 'Top 500 Companies' (2024)
Market Information
Included In
NIFTY TOTAL MARKETNIFTY MIDCAP 150NIFTY 500NIFTY MNCNIFTY LARGEMID250NIFTY MIDSML 400NIFTY PHARMANIFTY HEALTHCARENIFTY500 MULTICAPNIFTY M150 QLTY50
Details
ISIN: INE358A01014
Sector: Healthcare/Pharmaceuticals
Industry: Pharmaceuticals
Company Timeline
114+ Years of Excellence
8 Major Milestones
1910
Abbott establishes its presence in India.
1944
Incorporation of Abbott India Ltd as a legal entity.
1965
Commissioning of first manufacturing facility in Mumbai.
2003
Listed on the Bombay Stock Exchange and National Stock Exchange.
2010
Celebrated 100 years of operations in India.
2018
Launched new formulations in women's health and gastroenterology.
2022
Expanded rural outreach via digital healthcare initiatives.
2024
Recognized as a Best Workplace in Health & Wellness; ESG leadership reinforced.
Coming Soon: The Next Evolution
Contact Information
Registered Office
Unit No.3, Corporate Park, Sion - Trombay Road, Chembur
Tel: 022-50461000 / 2000 / 1119 / 1117 / 1116 / 67978888,
Fax: 022-50169400,
Email: investorrelations.india@abbott.com; webmaster@abbott.com
Website: abbott.co.in
Registrars
KFin Technologies Ltd
Tel: 040 - 67162222
Email: einward.ris@kfintech.com

Peer Comparison

Part ofNIFTY TOTAL MARKETNIFTY MIDCAP 150NIFTY 500NIFTY MNCNIFTY LARGEMID250NIFTY MIDSML 400NIFTY PHARMANIFTY HEALTHCARENIFTY500 MULTICAPNIFTY M150 QLTY50
S.No.Company NameCMP (₹)Market Cap (₹ Cr)Div Yld (%)NP Qtr (₹ Cr)Qtr Profit Var (%)Sales Qtr (₹ Cr)Qtr Sales Var (%)ROCE (%)ROE (%)Book Value (₹)EPS TTM (₹)TTMPE Ratio (₹)
Not Found Data

Coming Soon

Heatmap View

Premium Feature
CompanyCMP (₹)MCap (₹ Cr)EPS TTM (₹)
Not Found Data

Financial Ratios

Premium Feature
Company NameP/E (TTM)EPS (₹)D/ENPMGPMROE (%)ROCE (%)P/B
Not Found Data

Coming Soon